Characteristics of new adult users of mepolizumab with asthma in the USA

BACKGROUND: In the USA, over 25 million people have asthma; 5%–10% of cases are severe. Mepolizumab (Nucala) is an interleukin-5 antagonist monoclonal antibody; it was approved by the FDA in 2015 as add-on maintenance treatment of severe asthma for patients aged ≥12 years with an eosinophilic phenot...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Ann Chen, McMahon, Pamela M, Welch, Emily, McMahill-Walraven, Cheryl N, Jamal-Allial, Aziza, Gallagher, Mia, Zhang, Tancy, Draper, Christine, Kline, Anne Marie, Koerner, Leslie, Brown, Jeffrey S, Van Dyke, Melissa K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Asthma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572414/
https://www.ncbi.nlm.nih.gov/pubmed/34732517
http://dx.doi.org/10.1136/bmjresp-2021-001003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572414/
https://www.ncbi.nlm.nih.gov/pubmed/34732517
http://dx.doi.org/10.1136/bmjresp-2021-001003

Ejemplares similares